lower in the olanzapine group at each follow-up visit, the absolute change from baseline, which is what the authors studied in their statistical analysis, was actually greater in the risperidone group. This happened because the risperidone group had numerically more severe negative symptoms to begin with. The correct conclusion, therefore, is that olanzapine has poorer efficacy than risperidone for the treatment of the negative symptoms of schizophrenia, which is completely the opposite of what the authors stated in their title, abstract, results, discussion, and conclusions.
It is important that this error is recognized and recorded; else, it is likely that the paper will be highly cited to support a preference for olanzapine over risperidone for the attenuation of negative symptoms in the long-term management of schizophrenia.
The above notwithstanding, we do not believe that the new findings should be interpreted to support a preference for risperidone over olanzapine. This is because the negative symptom analysis was a part of the examination of many different outcome measures, and the statistical significance could have merely been a Type 1 error arising from the many statistical tests performed. In research, primary and secondary outcomes should be stated a priori, and greater emphasis should be laid on the former than on the latter. [2] There was no indication whatsoever that the authors [1] intended to study negative symptoms as their primary outcome.
As a final note, findings that are statistically significant are not necessarily clinically significant. In this study, the very small absolute differences for both negative symptoms and global ratings are an example in point.
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Black hairy tongue with olanzapine: A rare case report
General and neurological examinations of the patient revealed no abnormality. He was nonalcoholic and nonsmoker, and there was no history either of excessive coffee/tea intake or drug abuse. He was not suffering from any other disease except schizophrenia. There was no history of any other drug intake except olanzapine. His complete blood count, biochemical, and serological tests were normal. Scrape cytology of tongue lesion with May-Grunwald-Giemsa stain revealed abundant cellularity consisting of normal squamous cells and some elongated hair-like structures. Papanicolaou stain ruled out malignancy, and periodic acid-Schiff stain did not reveal fungal bodies.
Sir, A 45-year-old male patient presented with a complaint of black coating on the surface of his tongue. He was being treated with tablet olanzapine 20 mg daily. The patient was not taking any other medication. He noticed coating and black discoloration on the tongue after 16 days of therapy.
Examination of the oral cavity revealed black hair-like projections on the middle and posterior one-thirds of the dorsum of the tongue. The tip and lateral sides of the tongue were normal. Buccal mucosa and teeth were normal. There were no plaques in the oral cavity.
Swab from tongue patch was sterile. KOH mount from tongue scrapings did not reveal fungal elements. Fungal culture was negative. Biopsy of the lesion could not be done as the patient did not give consent for it.
Diagnosis of black hairy tongue (BHT) was made. Olanzapine was discontinued. Follow-up was done every week for 1 month. Black coating on the tongue decreased at the first follow-up (1 st week). It disappeared completely at the second follow-up (2 nd week) and remained so at the third and fourth follow-ups.
On Naranjo adverse drug reaction (ADR) probability scale, the score was five, which revealed a probable ADR. The ADR has been reported to the Pharmacovigilance Programme of India, with worldwide unique number IN IPC 201646573.
The exact mechanism of BHT induced by olanzapine is not known. It has been suggested that anticholinergic property of olanzapine has potential to induce BHT. [1, 2] To the best of our knowledge, there are only two published reports of BHT related to olanzapine. In one case, it was prescribed in combination with lithium [3] and in other with fluoxetine. [4] We report this case to highlight the occurrence of BHT as a rare ADR of olanzapine and to sensitize clinicians about it.
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Dermatological examination showed multiple coin-shaped hyperpigmented, well-demarcated patches varying in diameter from 1.5 cm to 6 cm over upper back, trunk, Sir, Fixed drug eruptions (FDEs) are uncommon cutaneous side effects of various drugs. Antidepressants are lesser known causative agents and selective serotonin reuptake inhibitors (SSRI) are considered even safer; however, we hereby report the first case of paroxetine-induced FDE.
A 40-year-old male patient presented with sudden onset, multiple hyperpigmented patches over upper back, trunk, abdomen, dorsum of hand, and posterior aspect of both thighs
